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Abstract
Introduction: Clinical studies suggest a direct influence of periodontal disease (PD) on serum inflammatory markers
and disease assessment of patients with established rheumatoid arthritis (RA). However, the influence of PD on
arthritis development remains unclear. This investigation was undertaken to determine the contribution of chronic
PD to immune activation and development of joint inflammation using the collagen-induced arthritis (CIA) model.
Methods: DBA1/J mice orally infected with Porphyromonas gingivalis were administered with collagen II (CII)
emulsified in complete Freund’s adjuvant (CFA) or incomplete Freund’s adjuvant (IFA) to induce arthritis. Arthritis
development was assessed by visual scoring of paw swelling, caliper measurement of the paws, mRNA expression,
paw micro-computed tomography (micro-CT) analysis, histology, and tartrate resistant acid phosphatase for osteoclast
detection (TRAP)-positive immunohistochemistry. Serum and reactivated splenocytes were evaluated for cytokine
expression.
Results: Mice induced for PD and/or arthritis developed periodontal disease, shown by decreased alveolar bone and
alteration of mRNA expression in gingival tissues and submandibular lymph nodes compared to vehicle.
P. gingivalis oral infection increased paw swelling and osteoclast numbers in mice immunized with CFA/CII. Arthritis
incidence and severity were increased by P. gingivalis in mice that received IFA/CII immunizations. Increased synovitis,
bone erosions, and osteoclast numbers in the paws were observed following IFA/CII immunizations in mice infected
with P gingivalis. Furthermore, cytokine analysis showed a trend toward increased serum Th17/Th1 ratios when P.
gingivalis infection was present in mice receiving either CFA/CII or IFA/CII immunizations. Significant cytokine increases
induced by P. gingivalis oral infection were mostly associated to Th17-related cytokines of reactivated splenic cells,
including IL-1β, IL-6, and IL-22 in the CFA/CII group and IL-1β, tumor necrosis factor-α, transforming growth factor-β,
IL-6 and IL-23 in the IFA/CII group.
Conclusions: Chronic P. gingivalis oral infection prior to arthritis induction increases the immune system activation
favoring Th17 cell responses, and ultimately accelerating arthritis development. These results suggest that chronic oral
infection may influence RA development mainly through activation of Th17-related pathways.
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Introduction
Periodontal disease (PD) is an immune-inflammatory in-
fection of the tooth-supporting structures. The disease
affects one-half of the US population over 30 years of
age and is the major cause of tooth loss among adults
[1]. For PD to develop, a microbial shift must occur
from a normally symbiotic microbiota into a dysbiotic
state [2]. While this exact shift is still being determined,
some key bacteria are consistently shown to be impor-
tant for PD. Porphyromonas gingivalis is a Gram-
negative pathogenic bacterium associated with increased
risk of periodontal breakdown and disease recurrence
[3]. In addition, P. gingivalis has been recently indicated
as a keystone pathogen of disease-provoking periodontal
microbiota [2]. P. gingivalis activates several innate im-
mune receptors, including toll-like receptor-2, toll-like
receptor-4, nucleotide-binding oligomerization domain-2,
and protease-activated receptor-2, which ultimately con-
tribute to disease initiation and progression [4-6]. Clas-
sically, periodontitis is considered a mixed T-helper type
(Th)1/Th2-driven disease, with a Th1 cytokine profile
being the major mediator in the early/stable lesion and a
dominance of a Th2 cells in the advanced/progressive le-
sion [7]. The role of Th17 cells in periodontitis is still
under investigation, with various lines of evidence sugges-
ting that it can either drive or protect against disease de-
velopment [8,9]. While the effect of P. gingivalis and the
role of cytokines in inflammation of the oral tissues have
been explored, only a few preclinical studies have evalu-
ated the systemic effect of periodontitis [10,11] and how it
may affect the development of other diseases in preclinical
models. The bidirectional association of periodontitis with
other diseases, including cardiovascular disease [12], dia-
betes mellitus [13], and rheumatoid arthritis (RA) [14],
underscores the relevance of understanding the cytokine
networks implicated in such associations.
RA is a chronic inflammatory autoimmune disease
that affects 1% of the population [15]. A complex cyto-
kine network is directly involved in specific immuno-
logical processes that promote autoimmunity, chronic
inflammation, and ultimately tissue destruction in RA
[16]. Cytokine modulation therapies, such as anti-tumor
necrosis factor (TNF) alpha, interleukin (IL)-6R, anti-IL-
23p19, and anti-IL-22 are shown to alter disease devel-
opment in preclinical and/or clinical settings [16-20].
Understanding the complex cytokine milieu that de-
velops in all stages of RA is therefore crucial for identi-
fying potential treatments for patients [16].
Accumulating clinical evidence supports a bidirectional
association between periodontitis and RA in the clinical
setting [14,21,22]. Some clinical studies suggest a direct ef-
fect of periodontal disease in established RA by decreased
serum erythrocyte sedimentation rate, C-reactive protein,
TNFα levels and improved Disease Activity Score in 28
joints after periodontal treatment is provided to RA
patients [23-25]. Although the effect of periodontal treat-
ment in RA needs to be confirmed in larger, controlled
trials, these results suggest a direct effect of periodontal
disease in RA. In addition, successful treatment of RA
patients with antibiotics against bacterial anaerobic infec-
tions suggests the involvement of bacteria in the etio-
pathogenesis of RA [26]. Only one report has shown that
prior P. gingivalis oral infection augments development of
collagen antibody-induced arthritis in mice [27]. While
analysis of C-reactive protein indicates that inflammation
is a main player in the additional effect observed, no fur-
ther cytokine analysis was performed. One very useful
model for studying RA is collagen-induced arthritis (CIA)
in rodents, which has not been explored in association
with periodontitis. Since both CIA and PD are inflamma-
tory and Th-driven diseases, an improved understanding
of the effect of chronic PD on the immune activation of
arthritis would be of value.
The present study was performed to determine the
role of P. gingivalis oral infection in modulating Th cell-
driven responses and arthritis development in CIA. Our
results indicate that P. gingivalis oral infection aug-
mented the innate immune response during arthritis de-
velopment. Our data demonstrate that mice infected
with P. gingivalis displayed increased Th17-driven res-
ponses in the serum via IL-17 and IFNγ, reactivated
splenocytes via IL-1β, IL-6, TNFα, transforming growth
factor beta (TGF-β), and IL-23, increased osteoclast




DBA1/J male mice (Jackson Laboratory, Bar Harbor, ME,
USA), 6 weeks old, were infected with P. gingivalis for
15 days (D0 to D15) and immunized 15 days later (D30)
with collagen II (CII) emulsified in either complete
Freund’s adjuvant (CFA) or incomplete Freund’s adjuvant
(IFA). Mice were sacrificed at baseline (D0), D30 (before
arthritis induction), D44 (14 days after arthritis induction),
and D73 (43 days after arthritis induction). All animal
experiments were approved by the Institutional Animal
Care and Use Committee of the University of Michigan
(Ann Arbor, MI, USA) and conformed to ARRIVE guide-
lines for preclinical studies.
Periodontitis induction
Mice were given sulfamethoxazole at 0.87 mg/ml and tri-
methoprim at 0.17 mg/ml (Hi-Tech Pharmacal Co. Inc.,
Armityville, NY, USA) in milli-Q water ad libitum for
10 days, followed by 3 days without antibiotics. For infec-
tion, mice were inoculated with an average 2 × 109 colony-
forming units of P. gingivalis strain W83 (BAA-308;
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ATCC, Manassas, VA, USA) in 100 μl phosphate-buffered
saline with 2% carboxymethylcellulose (Sigma-Aldrich,
St Louis, MO, USA) by oral gavage for 15 days as des-
cribed previously [28]. The vehicle group received car-
boxymethylcellulose alone.
Arthritis induction and evaluation
Mice were immunized with CII as described elsewhere
[29]. Briefly, chick CII at 4 mg/ml in 50 mM acetic acid
was emulsified in equal volumes of IFA or CFA. IFA was
composed of mannide monooleate and heavy paraffin
(Fisher Scientific, Hampton, NH, USA). CFA was com-
posed of IFA and freshly ground heat-killed Mycobac-
terium tuberculosis strain H37Ra (BD Biosciences, San
Jose, CA, USA). Fifty microliters were injected intrader-
mally at the base of the tail. Arthritis was scored by two
calibrated examiners (JTM, EAG) via a visual assessment
scoring (VAS) system using a scale of 0 to 4 per limb as
described previously [30]. Additionally, paws were mea-
sured in the medial–lateral and dorsal–ventral directions
by a blinded examiner utilizing a Lange skinfold caliper
(Beta Technology Inc., Santa Cruz, CA, USA) at D65,
D67, D70, and D72. Micro-computed tomography (micro-
CT), histologic scoring, and histomorphometric analysis
of the paws were performed.
Porphyromonas gingivalis infection assessment
For P. gingivalis colonization determination, the oral mi-
croflora was collected at baseline, and at D16, D30, D37,
D44, D51, D58, D65, and D73 post inoculation. Bacterial
infection was confirmed by polymerase chain reaction of
arginine–gingipain (201 base pairs) with minimum detec-
tion of 1 × 103 colony-forming units as described pre-
viously [10].
Splenocyte reactivation and cytokine analysis
At D0, D30, D44, D73, spleens were processed and reac-
tivated with 100 μg/ml highly purified lyophilized α1(II)
bovine collagen obtained as described previously [31].
Supernatants were collected after 5 days of culture and
evaluated for protein expression by Quantibody Mouse
TH17 array 1 (RayBiotech, Inc., Norcross, GA, USA).
Serum analysis
Sera collected at D0, D16, D30, D44 and D73 were eva-
luated for protein expression by Quantibody Mouse Th17
array 1 (RayBiotech, Inc.). Levels of anti-CII antibodies
were evaluated at D44 and D73. Briefly, 96-well plates
were coated overnight with 5 μg/ml chick CII, incubated
with mouse serum at 1:60, 1:240, and 1:960 dilutions for
1 hour, followed by incubation with alkaline phosphatase-
labeled goat anti-mouse IgG1, IgG2a, IgG2b, and IgG3
(SouthernBiotech, Birmingham, AL, USA) at 1:1,000 for
2 hours, and read at 405 nm absorbance.
Gene expression in gingival tissues, submandibular
lymph nodes, and inguinal lymph nodes
Tissues dissected at D0, D30, D44, and D73 were pro-
cessed for isolation of RNA using the TRIzol method
(Invitrogen, Rockville, MD, USA) and purified with the
RNeasy mini kit (Qiagen, Valencia, CA, USA). mRNA was
reverse transcribed into cDNA using SuperScript II
Reverse Transcriptase (Invitrogen). cDNA was then am-
plified using the TaqMan Universal PCR Master Mix
(Applied Biosystems, Carlsbad, CA, USA). The following
transcription factors were evaluated: T-bet, GATA-3,
RORγt, and Foxp3. Relative quantification of the data
generated was carried out using the comparative threshold
cycle for quantitative reverse transcription-polymerase
chain reaction method.
Micro-computed tomography analyses
Maxillae were fixed in 10% formalin and then trans-
ferred to 70% alcohol. Maxillae were scanned at a reso-
lution of 12 × 12 × 12 μm3 voxels using a micro-CT 100
cabinet cone-beam micro-CT system (Scanco USA, Inc.,
Wayne, PA, USA). Analysis was performed by a cali-
brated masked examiner (ADT) as previously described
with minor modifications [32]. The region of interest
encompassed the coronal region of supporting alveolar
bone from the mesial edge of the cementum–enamel
junction of M1 to the distal edge of the cementum–
enamel junction of M2, excluding root tissues. The
mean threshold gray-scale value was calculated and used
to derive the bone mineral content (mg) and tissue mi-
neral content (mg) using GEHC MicroView Analysis
Plus software (GE Healthcare, Little Chalfont, UK). Paws
cut above the ankle were placed in 4.5% neutral-buffered
zinc-free paraformaldehyde followed by 70% ethanol as
described elsewhere [33]. Analysis was performed by a
calibrated masked examiner (S-YS) as described pre-
viously [34]. The region of interest was defined in digits
2, 3, and 4. Areas of periosteal new bone and cortical
bone were discriminated based on the bone resolution
of 12 μm3 and obtained using the bone analysis com-
mand of GEHC MicroView Analysis Plus software (GE
Healthcare).
Histopathological analysis
Maxillae were decalcified in 10% ethylenediamine tetraa-
cetic acid (Acros, Fairlawn, NJ, USA) for 14 days and then
embedded in paraffin. Sagittal sections were obtained
from each maxilla at the molar region of M1, M2, and M3
and stained with hematoxylin and eosin for descriptive
analysis. Paws were decalcified in 14% ethylenediamine
tetraacetic acid (Acros) and embedded in paraffin. Trans-
verse paw sections were stained with hematoxylin and
eosin, and tartrate-resistant acid phosphatase (TRAP;
Sigma-Aldrich) for osteoclast detection. Histopathological
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scores of joint damage were determined for inflammatory
infiltrate, synovitis, cartilage destruction, and bone in-
volvement as described elsewhere [30]. For TRAP stai-
ning, slides were deparaffinized in xylene, hydrated in
serial ethanol, and incubated in a solution containing dia-
zotized fast garnet, napthol AS-BI phosphate, acetate, and
tartrate solution from the Acid Phosphatase, Leukocyte
(TRAP) kit (Sigma-Aldrich) as described previously [35].
Osteoclasts were identified as TRAP-positive cells and
counted utilizing Osteomeasure software (Osteometrics,
Inc., Decatur, GA, USA). Osteoclasts were counted in the
phalanges of digits 2, 3 and 4 and expressed as the bone
area and bone perimeter. The phalanges were selected by
the pathologist involved in the study as a bone region that
could be easily traced and quantified and was consistent
in all sections.
Statistical analysis
The study consisted of a total of 15 groups with eight mice
per group at four sacrificial time points (D0, D30, D44,
D73). Data are expressed as the mean ± standard error of
the mean. The differences among groups were statistically
assessed by the unpaired two-tailed Student’s t test (arth-
ritis development and mRNA expression), one-way ana-
lysis of variance (protein expression, antibodies, arthritis
scoring, and osteoclast numbers), Dunnet’s multiple com-
parison test (alveolar bone loss), or linear regression ana-
lysis (paw swelling). Comparisons were performed among
all groups. Data were analyzed by the GraphPad Prism 5.0
program (GraphPad Software, La Jolla, CA, USA). In all
tests, P <0.05 was considered statistically significant.
Results
Periodontal disease development
Confirmation that mice were chronically infected with
P. gingivalis both at the time of arthritis induction (D30)
and during arthritis development (D30 to D65) was
achieved via polymerase chain reaction of the oral
microflora using arginine–gingipain (Table 1). At D73,
P. gingivalis colonization was below the level of detec-
tion for mice infected with P. gingivalis and immunized
with CFA/CII and IFA/CII. In comparing the extent of
alveolar bone loss, micro-CT analysis demonstrated de-
creased bone mineral content and tissue mineral content
in all treatment groups independent of the presence of
P. gingivalis when compared with vehicle (Dunnet’s
multiple comparison, P <0.05 and P <0.01) (Figure 1A).
Gingival tissue showed increased RORγt expression at
D44 in the P. gingivalis (Pg)-CFA/CII and IFA/CII
groups compared with the Pg group (Figure 1B), con-
firming that induction of arthritis could induce and in-
fluence periodontal disease development. At D44 and
D73, a decrease in the submandibular lymph node ex-
pression of T-bet was observed if P. gingivalis-infected
mice were immunized with CFA/CII compared with
mice that received P. gingivalis alone. The expression of
GATA-3 was also altered by P. gingivalis oral infection,
shown by downregulation in the Pg-IFA/CII group when
compared with the IFA/CII group at D44 and D73, and
in the Pg-CFA/CII group when compared with the CFA/
CII group at D73 (Figure 1B). Mice immunized with
IFA/CII had increased GATA-3 expression at D44 and
D73 compared with mice in the Pg group. Upregulation
Table 1 Porphyromonas gingivalis oral colonization during periodontitis and arthritis development
Group Day 0 Day 16 Day 23 Day 30 Day 37 Day 44 Day 51 Day 58 Day 65 Day 73
Baseline 0/8
D30 Vehicle 0/8 0/8
D30 Pg 0/8 6/8 6/8 4/8
D44 Vehicle 0/8 0/8
D44 Pg 0/8 8/8 8/8 8/8 8/8 8/8
D44 CFA 0/8 0/8
D44 Pg-CFA 0/8 8/8 8/8 8/8 8/8 8/8
D44 IFA 0/8 0/8
D44 Pg-IFA 0/8 8/8 8/8 8/8 8/8 8/8
D73 Vehicle 0/8 0/8
D73 Pg 0/8 8/8 8/8 8/8 7/8 8/8 8/8 8/8 6/8 8/8
D73 CFA 0/8 0/8
D73 Pg-CFA 0/8 6/8 7/8 8/8 8/8 8/8 6/8 8/8 8/8 0/8
D73 IFA 0/8 0/8
D73 Pg-IFA 0/8 4/8 8/8 8/8 5/8 8/8 7/8 2/8 6/8 0/8
Murine oral microflora collected at timeline days D0, D16, D23, D30, D37, D44, D51, D58, D65, and D73 were evaluated by polymerase chain reaction of arginine–gingipain
(201 base pairs). Values represent the number of infected mice/number of total mice in each group (n= 8). Mice that were not infected with P. gingivalis were not
evaluated weekly, but only at baseline and sacrifice. CFA, complete Freund’s adjuvant; IFA, incomplete Freund’s adjuvant; Pg, P. gingivalis.
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of Foxp3 was observed at D73 in mice treated with
P. gingivalis, CFA/CII, or IFA/CII when compared with
vehicle. This datum demonstrates that an active Th cell
response was developing in the oral-related tissues by
both CII immunizations and by oral infection with
P. gingivalis. Finally, histological sections confirmed
chronic periodontitis by the presence of enlarged blood
vessels, irregular alveolar bone crest, tissue remodeling
and dense fibroblast populations above the crestal bone
of the mesial M1 region as well as the distal M1 and
mesial M2 region in mice from all treatment groups
(Figure 1C). These features were not present in mice
Figure 1 Periodontal disease development in the periodontitis and arthritis mouse models. (A) Alveolar bone evaluated at timeline day
D73 by micro-computed tomography analysis for bone mineral content and tissue mineral content. Mice that received either Porphyromonas
gingivalis (Pg), arthritis induction by complete Freund’s adjuvant (CFA)/collagen II (CII), arthritis induction by incomplete Freund’s adjuvant
(IFA)/CII, or both P. gingivalis and arthritis induction had less alveolar bone compared with vehicle, representing increased bone loss. Data
represented as mean ± standard error of the mean, n = 8/group, P <0.05, Dunn’s multiple comparison test. (B) Gingival tissues and submandibular
lymph nodes evaluated for mRNA expression showed increased expression of RORγt, T-bet, GATA-3, and Foxp3 in mice that received all
treatments (Student’s t test, *p≤0.05, **p≤0.01, ***p≤0.001). (C) Representative histological sagittal sections of the mesial region of M1 and the
interproximal region between M1 and M2 stained with hematoxylin and eosin from mice in the vehicle group and mice that developed chronic
periodontal disease. M1 and M2, molars 1 and 2; A, alveolar bone crest; yellow arrows, presence of a dense fibroblast population and disorganized
tissue; red arrows, presence of blood vessels; blue arrows, irregular alveolar bone crest, indicating bone resorption.
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from the vehicle group, and interestingly no major addi-
tive effect of treatment combinations (P. gingivalis with
CII immunizations) could be observed. In summary,
immunization with CII or infection with P. gingivalis in-
duced the development of chronic PD in the mice with
corresponding development of Th cell responses.
Arthritis progression is increased by P. gingivalis oral
infection in mice challenged for arthritis with CFA/CII
VAS showed no significant differences in the final arth-
ritis incidence between mice in the Pg-CFA/CII and
CFA/CII groups (7/8 and 8/8 respectively). Interestingly,
changes in the severity of arthritis were induced by
P. gingivalis after arthritis had developed in the entire
paw (VAS 4). Paw swelling was significantly increased in
both the medial–lateral and dorsal–ventral dimensions
once arthritis developed in the entire hind paw in mice
orally infected with P. gingivalis and further immunized
with CFA/CII (Figure 2A,B,C). The same pattern was
observed in the front paws (data not shown). Paws with
VAS of 4 were further analyzed for bone loss by micro-
CT and the presence of active osteoclasts by TRAP
staining. While our results did not show significant dif-
ferences in amount of bone resorption by micro-CT ana-
lysis, mice in the Pg-CFA/CII group had an increased
number of osteoclasts/bone area when compared with
the CFA/CII group alone (Figure 2D). These findings
demonstrate that even with a robust model for arthritis
induction utilizing adjuvant that contains M. tuberculosis
fragments within CFA/CII in the process of immu-
nization, P. gingivalis chronic oral infection altered the
progression of arthritis by increasing paw swelling and
osteoclast recruitment.
Arthritis development is altered by P. gingivalis oral
infection in mice induced for arthritis with IFA/CII
Increased incidence and severity were observed in mice
from the Pg-IFA/CII group compared with the IFA/CII
group alone (D58 in the Pg-IFA/CII group and D65 in
the IFA/CII group, Figure 3A). In addition, the final
mean VAS and mean number of arthritic paws/group
was significantly higher at D73 in mice from the Pg-
Figure 2 Increased swelling and osteoclast numbers in mice with Porphyromonas gingivalis oral infection. Paws measured in the
medial–lateral and dorsal–ventral dimensions at timeline days D65, D67, D70, and D72 (35, 37, 40, and 42 days after complete Freund’s adjuvant
(CFA)/collagen II (CII) immunization) were compared with (A) paws with visual assessment score of 0 (no arthritis) and (B) paws that developed a
visual assessment score of 4. (C) Representative figures of hind paws that developed score 0 (upper panel), score 4 with medial–lateral
measurement of 4 mm in mice from the CFA/CII group (middle panel), and score 4 with medial–lateral measurements of 5.0 mm and 5.5 mm in
mice from the P. gingivalis (Pg)-CFA/CII group (lower panel). Error bars represent ± standard error of the mean (SEM) of four to six mice per group,
P <0.05, linear regression analysis. (D) No differences between groups were observed in paws evaluated by micro-computed tomography for
periosteal new bone and cortical bone destruction bone area; however, the osteoclast number by tartrate-resistant acid phosphatase (TRAP)-positive
staining was significantly increased in mice with oral P. gingivalis. Error bars represent ± SEM of four to six mice per group, P <0.05, Student’s t test.
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IFA/CII group compared with the IFA/CII group
(Figure 3A). Histological scoring of the paws confirmed
the clinical findings, demonstrating that mice gavaged
with P. gingivalis and immunized with IFA/CII displayed
increased synovial thickening and pannus formation as
well as bony erosions when compared with IFA/CII
alone (Figure 3B). Paws evaluated by TRAP staining
showed that mice infected with P. gingivalis followed by
IFA/CII immunization had an increased number of oste-
oclasts/bone perimeter (Figure 3C). In sum, these results
show that a chronic oral P. gingivalis infection initiated
prior to IFA/CII immunization increased the incidence
and severity of CIA and was associated with increased
osteoclast numbers.
Porphyromonas gingivalis increased serum Th17 responses
It was anticipated that the immunological development of
arthritis in IFA/CII groups might be slower than in CFA/
CII groups [36]. Indeed, our results show that mice immu-
nized with IFA/CII had a significantly lower anti-CII anti-
body response compared with mice immunized with
CFA/CII at D44, but reached similar values at D73, inde-
pendent of oral infection with P. gingivalis (Figure 4A).
This demonstrates that P. gingivalis did not have an effect
on the antibody response to CII. Rather than the absolute
value of an individual cytokine, the balance of serum Th17
and Th1 responses was previously shown to be associated
with the degree of joint inflammation, with increased
IL-17A/IFNγ ratios present in mice that developed more
severe CIA [30]. Interestingly, the balance of serum
IL-17A/IFNγ showed a trend to be increased (P = 0.09)
at D44 if P. gingivalis oral infection was present in mice
developing arthritis in the CFA/CII group compared
with CFA/CII alone, and a nonsignificant trend in
IL-17F/IFNγ ratios (Figure 4B). An increased trend in
IL-17F/IFNγ (P = 0.055) was found at D73 if mice had
P. gingivalis oral infection and IFA/CII immunization
when compared with mice in the vehicle group. Our
results show that P. gingivalis oral infection favored a
Th17 systemic response by increasing IL-17 levels and
decreasing IFNγ serum levels.
Porphyromonas gingivalis increased Th17 responses in
collagen II-reactivated splenocytes
Supernatants from murine splenocytes treated with CII
were evaluated for protein expression. Mice with oral P.
gingivalis infection demonstrated significantly increased
levels of Th1-related, Th2-related and Th17-related
Figure 3 Porphyromonas gingivalis oral infection increased arthritis development in mice immunized with collagen II in incomplete
Freund’s adjuvant. Mice infected with P. gingivalis (Pg) in the oral cavity for 15 days were immunized with incomplete Freund’s adjuvant
(IFA)/collagen II (CII) 15 days later as described in Methods. (A) Arthritis development and severity was scored by a visual assessment score on a 0
to 4 scale. The total number of arthritic paws was significantly higher in mice with P. gingivalis oral infection and IFA/CII immunization compared
with IFA/CII alone. (B) Paws collected at D73 demonstrated increased synovitis and greater bone involvement if mice had P. gingivalis oral infection
and IFA/CII immunization compared with IFA/CII alone. (C) Paws collected at timeline D0, D30, D44, and D73 were scored for tartrate-resistant acid
phosphatase (TRAP)-positive cells. Increased osteoclasts numbers were observed at D73 if mice had P. gingivalis infection and IFA/CII immunization.
Error bars represent ± standard error of the mean of eight mice per group, P <0.05, Student’s t test and analysis of variance.
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cytokines once mice were immunized with either CFA/
CII or IFA/CII when compared with mice that had no
P. gingivalis infection. Mice in the Pg-CFA/CII group
had significant increased expression of Th2-related cyto-
kines IL-5 and IL-13 (Figure 5A,B), as well as Th17-
related cytokines IL-1β, IL-6, and IL-22 when compared
with CFA/CII alone at D73 (Figure 5C). The majority of
changes induced by P. gingivalis oral infection were ob-
served on D44 (Figure 6A,B,C), and less were observed
on D73 (Figure 6D). At D44, mice in the Pg-IFA/CII
group had significantly increased levels of Th1-related
cytokine IL-12p70 (Figure 6A), Th2-related cytokine
IL-5 (Figure 6B), and Th17-related cytokines IL-1β,
TNFα, TGF-β, and IL-23 (Figure 6C) when compared
with IFA/CII alone. At D73, Th17-related cytokines
TGF-β and TNFα were significantly upregulated in CII
immunized mice independent of the oral P. gingivalis in-
fection, while IL-6 levels were significantly upregulated
independent of CII reactivation if mice were infected
with P. gingivalis (Figure 6D). mRNA isolated from in-
guinal lymph nodes demonstrated increased expression
of T-bet in both the Pg-CFA/CII and CFA/CII groups
compared with vehicle at D44 (data not shown). In sum-
mary, our results show the expression of factors involved
in the development of Th1, Th2, and Th17 cells, but the
majority of the differences between mice that received
oral P. gingivalis infection followed by CII immunization
compared with CII immunization alone were observed
Figure 4 Effect of Porphyromonas gingivalis on serum responses after collagen-induced arthritis induction. Mice gavaged with P. gingivalis
(Pg) in the oral cavity for 15 days (D0 to D15) were immunized with collagen II (CII) emulsified in complete Freund’s adjuvant (CFA) and incomplete
Freund’s adjuvant (IFA) 15 days later (D30), as described in Methods. (A) Antibodies to CII were measured by enzyme-linked immunosorbent assay at
D44 and at D73. Serum collected at D44 and D73 were evaluated for interleukin (IL)-17A/interferon (IFN)γ and IL-17 F/IFNγ ratios in (B) CFA/CII
immunizations and (C) IFA/CII immunizations. Error bars represent ± standard error of the mean of eight mice per group, P <0.05, analysis of variance
and Student’s t test. P <0.2 results are also presented.
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in Th17-related cytokines. Although some cytokines can
be expressed by T cells and B cells in the mixed splenic
population we evaluated in vitro, the majority of cyto-
kines are expressed (not exclusively) by monocytes/mac-
rophages and dendritic cells, including IL-1β, IL-6,
IL-22, IL-12p70, TNFα, IL-6, and IL-23. These results
suggest that the oral P. gingivalis infection initiated prior
to arthritis induction sensitized innate immune cells and
increased cytokine responses favoring Th17 cells, which
ultimately led to increased arthritis development and
progression.
Discussion
RA is a chronic inflammatory disease clinically associ-
ated with PD [14]. Some studies demonstrate that pa-
tients with RA demonstrate clinical and serological
improvements if periodontal therapy is provided [23-25],
suggesting that a chronic oral infection can alter estab-
lished RA. Here we show for the first time that a chronic
oral infection with bacterium P. gingivalis favored Th17-
driven responses that ultimately influenced CIA develop-
ment and progression.
Both CIA and PD are inflammatory, Th cell-mediated
diseases [7,30]. Cytokine modulation therapies, such as
anti-TNFα, anti-IL-23p19 and anti-IL22, are shown to
alter disease development in preclinical and/or clinical
settings [16-19]. Interestingly, other infections have been
demonstrated to affect proinflammatory cytokines and
CIA development [37,38]. Helminth product ES-62 can
alter the Th17 network at multiple sites and ultimately
protects mice from developing CIA [39]. Understanding
how chronic periodontitis can modulate the cytokine
network driving arthritic immune responses before cli-
nical bone destruction takes place is therefore of great
interest in relation to developing preventive periodontal
therapies in susceptible populations.
Several immunological processes need to occur for
arthritis to develop, including activation of antigen-
presenting cells by pattern-recognition receptors, T-cell
and B-cell polarization, and finally osteoclast activation.
Arthritis induction with CII in combination with either
CFA or seldom-used IFA allowed identification of the
immunological phase of arthritis development most pro-
nouncedly affected by P. gingivalis. The significantly lower
arthritis incidence and severity and higher day of onset of
arthritis in mice immunized with CII and IFA has led to
the use of CII and CFA for arthritis induction in the great
majority of the studies [36,40]. The effect of P. gingivalis
Figure 5 Mice exposed to Porphyromonas gingivalis prior to immunization with collagen II and complete Freund’s adjuvant exhibit
increased splenic T-helper type 17-related responses. Murine splenocytes were isolated from mice that received 15 oral gavages of P. gingivalis
(Pg) followed by complete Freund’s adjuvant (CFA)/collagen II (CII) immunization at day D30 according to Methods. Splenocytes collected at D73 were
reactivated in vitro with CII. Supernatants evaluated for protein expression demonstrated increased expression of (A) T-helper type (Th)1-related
cytokine interleukin (IL)-5, (B) Th2-related cytokine IL-13, and (C) Th17-related cytokines IL-1β, IL-6, and IL-22 if mice had P. gingivalis infection in
addition to CFA/CII immunization. Error bars represent ± standard error of the mean of eight mice per group, P <0.05, analysis of variance followed by
Tukey’s multiple comparison test, and Student’s t test.
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in CIA development was observed in mice immunized
with either CFA/CII or IFA/CII (Figures 2 and 3). How-
ever, the diminished activation of the innate immune re-
sponse, including antigen-presenting cells, by the absence
of M. tuberculosis in IFA/CII brought out increased effects
of P. gingivalis in CIA development. This observation sug-
gests that the majority of effects induced by P. gingivalis
were during the innate immune response. Our in vitro
results strengthen this finding by showing that the majority
of cytokines upregulated by P. gingivalis were derived
frommonocytes/macrophages and dendritic cells (Figures 5
and 6). The results therefore indicate that the most pro-
nounced effects induced by P. gingivalis in CIA were by
sensitizing innate immune cells favoring a Th17 response.
It was previously shown that the balance of Th1, Th2,
and Th17 responses could control the immune events
leading to bone destruction. Our data showed a trend
towards increased Th17/Th1 ratios in mice with oral
P. gingivalis induced for arthritis with either CFA/CII or
IFA/CII (Figure 4B,C), which was correlated with in-
creased paw swelling, accelerated development of CIA,
and increased osteoclast numbers (Figures 2 and 3). In
accordance with our results, a higher Th17/Th1 ratio
has been observed in mice that develop more severe
arthritis [30]. The cytokine network alteration induced
by P gingivalis in the serum was further validated by a
spleen cell in vitro assay. Increased expression of Th2-
related cytokines IL-5 and IL-13 and Th17-related cyto-
kines IL-1β, IL-6, and IL-22 at D73 were found in mice
infected with P gingivalis prior to CFA/CII immuniza-
tions (Figure 5). IL-5 and IL-13 are cytokines related to
arthritis suppression [41,42], while tissue-destructive
cytokines IL-1β and IL-6 induce Th17 cells and promote
osteoclastogenesis [43]. IL-22, which is significantly up-
regulated in the Pg-CFA/CII group (Figure 5E), can be
expressed by Th17 cells and assists in promoting inflam-
mation [44]. In the IFA/CII groups, the levels of IL-5
and IL-12 (Figure 5A,B) and of Th17-related cytokines
Figure 6 Mice exposed to Porphyromonas gingivalis prior to immunization with collagen II and incomplete Freund’s adjuvant
generates increased splenic T-helper type 17-related responses. Murine splenocytes were isolated from mice that received 15 oral gavages
of P. gingivalis (Pg) followed by incomplete Freund’s adjuvant (IFA)/collagen II (CII) immunization at day D30 according to Methods. Splenocytes
were collected at D44 and D73 and reactivated in vitro with CII. Supernatants collected and evaluated for protein expression at D44
demonstrated increased (A) T-helper type (Th)1-related response via interleukin (IL)-12p70, (B) increased Th2-related response via IL-5, and
(C) increased Th17-related responses via IL-1β, tumor necrosis factor (TNF)-α, transforming growth factor beta (TGF-β), and IL-23 if mice had
P. gingivalis infection in mice immunized with IFA/CII. (D) At D73, immunized mice demonstrated increased expression of TNFα and TGF-β, with
IL-6 being significantly upregulated independent of in vitro reactivation. Error bars represent ± standard error of the mean of eight mice per
group, P <0.05, analysis of variance followed by Tukey’s multiple comparison test, and Student’s t test.
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IL-1β, TNFα, TGF-β, and IL-23 were significantly higher
at D44 if mice had P. gingivalis infection (Figure 6C).
Interestingly, inflammatory cytokines such as TNFα and
IL-1β are known to potentiate the effects of IL-17 and
IL-17 F [45]. IL-23 is known to be one essential factor
required for the expansion of pathogenic Th17 cells and
development of autoimmunity [46]. At D73, increased
expression of IL-6 was observed in mice immunized
with P. gingivalis, indicating that a Th17 response was in
the process of development. TGF-β, which was present
at D73 independent of P. gingivalis infection, is known
to promote differentiation of cells into Th17 cells in the
presence of IL-6 [43], which was being constitutively
expressed by splenocytes independent of CII reactivation
in the Pg-IFA/CII group (Figure 6D). Th17-related cyto-
kines promote osteoclastogenesis either directly by in-
ducing RANKL or indirectly by inducing IL-17 [16,43].
Because mice infected with P. gingivalis showed in-
creased arthritis progression, development and osteo-
clast numbers, we conclude that the net effect of Th17
destructive response was stronger than the protection
that could be provided by Th1-related and Th2-related
cytokines.
The timing of cytokine modulation during the im-
munological events that take place once CIA is induced
is shown to be an important factor to consider when
modifying the final arthritis development. For example,
neutralizing IL-23 before clinical signs of arthritis take
place can suppress CIA severity, while anti-IL-23p19
antibody treatment after the first signs of CIA does not
affect the disease development [18]. In accordance with
our results, it has been previously shown that prior
P. gingivalis oral infection increased arthritis develop-
ment in the collagen-antibody induced arthritis model
[27]. Interestingly, P. gingivalis infection initiating after
arthritis induction was shown to have no effects on
arthritis development in the pristane-induced model of
arthritis [47]. Future studies with different time frames
between disease inductions will assist in clarifying
whether the influence of P. gingivalis in arthritis deve-
lopment is dependent on timing.
The oral gavage model with P. gingivalis is known as a
classical method for inducing periodontitis in susceptible
rodents and can be utilized for studying the association of
periodontal disease with other systemic conditions [48].
While the effect of arthritis induction on periodontitis
development was not the focus of this study, we observed
alveolar bone loss in mice that received either CII immu-
nizations or P. gingivalis oral infection, which was further
supported by increased local expression of several tran-
scription factors (Figure 1). The development of periodon-
titis during arthritis induction is in agreement with several
murine studies, including in the CIA model [49], the adju-
vant arthritis model [50], the chronic-antigen induced
arthritis model [51], and the pristane-induced arthritis
model [47]. Periodontitis development in the CIA model
was characterized by increased osteoclast activity and
adipocyte production, and decreased osteoblastic activity
in alveolar bone cells. These results indicate that the local
alveolar cells develop an altered behavior with immuniza-
tions that leads to alveolar bone destruction. However, the
Th cell responses and oral microflora in these mice were
not evaluated. In our study, we showed that immunized
mice did not have an increase in P. gingivalis colonization
(Table 1), ruling out the possibility that alveolar bone loss
in the CFA/CII and IFA/CII groups was directly due to
oral P. gingivalis infection. Recently, a comprehensive
analysis of the subgingival microbiota of patients with
new-onset and chronic RA demonstrated that bacterium
Anaeroglobus geminatus correlated with the presence of
anti-citrullinated protein antibodies and rheumatoid fac-
tor, while Prevotella and Leptotrichia species were the only
taxa observed in patients with new-onset RA irrespective
of PD status [52]. This implies that the oral microflora
shifts may be distinct in the RA population and that ad-
ditional periodontal bacteria should be explored in the
context of arthritis. Interestingly, control of the oral
microflora with antimicrobial treatment stopped alveolar
bone loss in both the pristine model of arthritis [47] and
the chronic antigen-induced arthritis models [51]. Al-
though no further characterization of the microflora was
performed in that study, this observation suggests that a
microbial shift occurs in mice induced for arthritis. Inte-
restingly, our analysis showed that mice induced for arth-
ritis had a more sporadic oral infection with P. gingivalis
compared with mice with no arthritis induction (Table 1).
This observation indicates that the oral microflora of im-
munized mice was interfering with P. gingivalis colo-
nization and strengthens the hypothesis that a microbial
shift occurs in immunized mice. Increasing the under-
standing of the oral microflora and potential microbiota
shift that may occur with arthritis induction and develop-
ment is of interest. Exploration of the effect of additional
periodontal bacteria in arthritis development is of interest.
Still, RA patients with severe periodontitis show a more
robust antibody response against P. gingivalis than non-
RA controls [53], suggesting that infection with this bac-
terium in RA patients could be important.
Conclusion
Our data indicate that alveolar bone loss occurs in the
presence of oral P. gingivalis or CII immunization. Oral in-
fection of mice with P. gingivalis altered the immune de-
velopment of arthritis primarily via Th17-driven responses,
with increased paw swelling, accelerated development,
higher incidence of arthritis, and increased paw osteoclast
numbers. Our data also suggest that the more pronounced
effects observed were related to an augmentation of the
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innate immune response. These results are important in
furthering our understanding for the potential of an oral
chronic infection in altering arthritis condition in suscep-
tible patients, and may have important implications for de-
veloping future preventive strategies.
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